Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING
JIB

New Culture Technique Will Promote the Study of Leukemic Stem Cells

By BiotechDaily International staff writers
Posted on 02 Apr 2014
Image: Acute myeloid leukemia cells presenting anomalies in standard growth conditions (top). Acute myeloid leukemia cells preserving their leukemic cell features following in vitro culture with the two chemical molecules referred to in the study (below) (Photo courtesy of the Université de Montréal).
Image: Acute myeloid leukemia cells presenting anomalies in standard growth conditions (top). Acute myeloid leukemia cells preserving their leukemic cell features following in vitro culture with the two chemical molecules referred to in the study (below) (Photo courtesy of the Université de Montréal).
A multidisciplinary team of cancer researchers has developed a method for maintaining leukemic stem cells (LSCs) in culture, which will aid in the study of this class of cancer cells and the development of new drugs.

It has proven difficult to study LSCs, as currently available culture conditions do not prevent their spontaneous differentiation into full-blown acute myeloid leukemia (AML) cells. To overcome these constraints the “Leucégène” research group of investigators at the Université de Montréal (Canada) conducted a high-throughput chemical screen to identify small molecules that could inhibit differentiation and support LSC activity in vitro.

They reported in the February 23, 2014, online edition of the journal Nature Methods that they were able to identify two chemical compounds that, when added to the culture medium, could maintain functional human LSCs alive for at least seven days in vitro. One of the compounds suppressed the aryl-hydrocarbon receptor (AhR) pathway, which is inactive in vivo but rapidly activated ex vivo in AML cells. The other compound, UM729, collaborated with AhR suppressors in preventing AML cell differentiation.

These findings provide newly defined culture conditions for improved ex vivo culture of human LSCs and primary AML cells. “This research breakthrough demonstrates the advantage of working in a multidisciplinary team like the “Leucégène” research group,” said senior author Dr. Guy Sauvageau, professor of medicine at the Université de Montréal. “Access to cells of leukemia patients and to IRIC’s [The Institute for Research in Immunology and Cancer of the Université de Montréal] state-of-the-art facilities are also key factors in pursuing ground-breaking research.”

Related Links:

Université de Montréal



comments powered by Disqus

Channels

Drug Discovery

view channel
Image: S-649266 has more robust antibacterial activity than established antibiotics against multidrug-resistant bacteria (Photo courtesy of Shionogi).

Novel Antibiotic Shows Potential for Broad Range of Infections

The emergence of bacterial resistance to known antibacterial agents is becoming a major challenge in treating the infection caused by multi drug resistant (MDR) bacteria. In order to treat bacterial... Read more

Lab Technologies

view channel
Image: Leica Microsystems launches the inverted research microscope platform Leica DMi8 (Photo courtesy of Leica Microsystems).

New Inverted Microscope Designed to Readily Adapt to Changing Research Demands

A new inverted microscope for biotech and other life science laboratories was designed to readily accommodate modifications and upgrades to allow it to keep current with changing research demands and interests.... Read more

Business

view channel

Collaboration of Mayo Clinic and IBM Cognitive Computer Devised to Improve Clinical Trial Research

The Mayo Clinic (Rochester, MN, USA) and IBM (Armonk, NY, USA) recently announced plans to pilot Watson, the IBM cognitive computer, to match patients more rapidly with suitable clinical trials. A proof-of-concept phase is currently ongoing, with the intent to introduce it into clinical use in early 2015.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.